Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337102 | 0.81 | ESR1 (0.40) | PTGER1LMNAALDH1A1KMT2AHSD17B10 | |
| SCHEMBL19337065 | 0.81 | ALDH1A1 (0.47) | LMNAALDH1A1KMT2AHSD17B10ESR1 | |
| SCHEMBL9822673 | 0.79 | LMNA (0.42) | PTGER1LMNAALDH1A1KMT2AHSD17B10 | |
| SCHEMBL8020313 | 0.73 | MGLL (0.42) | LMNAALDH1A1MGLLGABRA1GABRB2 | |
| SCHEMBL462452 | 0.73 | AR (0.49) | LMNAALDH1A1KMT2ATSHRMGLL | |
| SCHEMBL3703551 | 0.72 | MGLL (0.45) | LMNATSHRMAPK1MGLLGABRA1 | |
| SCHEMBL30901799 | 0.72 | MGLL (0.45) | LMNATSHRMAPK1MGLLGABRA1 | |
| Hydrochloric Acid SCHEMBL5510044 | 0.71 | AR (0.47) | LMNAALDH1A1KMT2ATSHRMGLL | |
| SCHEMBL2495979 | 0.71 | MGLL (0.41) | LMNAALDH1A1KMT2ATSHRMAPK1 | |
| SCHEMBL5698455 | 0.71 | TSHR (0.53) | LMNAALDH1A1KMT2AHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683099-B2 | FOR THERAPY OF ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6677375-B2 | TREATING CARDIOVASCULAR DISEASES | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-12 | — | — | US | disclosed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | PTGER1 2023/4885LMNA 1614/4885ALDH1A1 2277/4885 |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | PTGER1 2023/4885LMNA 1614/4885ALDH1A1 2277/4885 |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | PTGER1 2023/4885LMNA 1614/4885ALDH1A1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.